The UK’s Medicines and Healthcare products Regulatory Agency published a strategy on October 14, 2026, setting out how it intends to regulate artificial intelligence and personalised medicine through 2030, promising to cut scientific advice review times from 90 days to 45 and to halve the assessment window for qualifying Phase 1 clinical trials to just 14 days.
A Regulator Trying to Keep Pace
MHRA chief executive Lawrence Tallon framed the strategy as a response to forces the agency says are already reshaping medicine faster than its rulebook can keep up. “These ground-breaking developments challenge traditional regulatory models,” Tallon said, referring to cell and gene therapies, personalised medicine, and advanced diagnostics, with AI named as a central driver reshaping both how products are regulated and how healthcare companies operate. The document, reported by the Regulatory Affairs Professionals Society, lays out a multi-year roadmap built around three stated aims: becoming more patient-centred, getting safe and effective treatments to patients faster, and expanding data connectivity and global regulatory influence.
New Machinery for AI Oversight
The centerpiece of the AI-specific commitments is a new MHRA Centre for AI and Digital Health, intended to build internal expertise, support developers navigating the approval process, and clarify what the agency expects from AI-driven devices and medicines. The agency says it wants to lead globally in regulating AI as a medical device, continuously monitor how AI systems perform once deployed in the real world rather than relying only on pre-market testing, and expand so-called Predetermined Change Control Plans — a mechanism that lets AI software be updated and retrained after approval without triggering a full new review each time. The MHRA also plans to explore “foundation model Master Files,” a system that would let a single underlying AI model be referenced across multiple product submissions instead of re-evaluated from scratch.
Tools Built With AI, For Regulating AI
In a twist, the agency intends to use AI itself to speed up its own processes. It plans to deploy an AI-enabled Clinical Trial Protocol Checker that would flag common reasons trial applications get rejected before sponsors submit them, aiming to reduce back-and-forth delays. The strategy also calls for using AI to analyze safety data and spot emerging risk signals sooner than traditional post-market surveillance allows, and it commits to publishing an AI Medicines Development Action Plan within the next year.
Leaning on Other Regulators
Facing what it describes as limited resources, the MHRA is leaning heavily on international cooperation rather than trying to evaluate every product from scratch. The strategy commits to expanding reliance and recognition routes with trusted regulators, explicitly including the U.S. Food and Drug Administration, and to exploring mutual recognition specifically for medical devices, building on the existing US-UK pharmaceutical partnership. It will continue to recognize CE-marked devices from the European Union, and following a 2026 consultation, is considering indefinite recognition in Great Britain of devices that already comply with EU Medical Device Regulation standards. The agency plans to pursue this through bodies including the Access Consortium, the International Medical Device Regulators Forum, and the Health AI Global Regulatory Network.
Industry Reaction: Relief Mixed With Wait-and-See
Trade coverage framed the industry response as broadly positive, with pharmaceutical and device companies having pushed for years for faster, more predictable UK review timelines that increasingly lag behind the pace of AI product development. At the same time, several of the strategy’s most consequential AI provisions — the dedicated AI device framework, the predetermined change control guidance, and the foundation model Master File concept — remain commitments on paper rather than finished rules. A government response has indicated draft guidance on change control plans for adaptive AI is due by December 2026, with a formal consultation on revised software and AI device classification not expected until spring 2027, meaning companies will be operating under current rules for some time yet even as the direction of travel becomes clearer.
What to Watch
A National Commission into the Regulation of AI in Healthcare is expected to deliver its own recommendations to the MHRA later in 2026, which could reinforce or complicate pieces of this strategy. For now, the plan functions mostly as a statement of intent and a timeline for follow-up documents rather than a complete rulebook — but it signals that the UK, like the FDA in the United States, is trying to move from treating AI medical software as a novelty requiring case-by-case scrutiny toward building standing infrastructure, specialized expertise, and faster pathways built specifically around how AI products are developed, updated, and monitored over their lifetime.
Photo: Tara Winstead / PEXELS via Pexels
